A theranostic prodrug delivery system based on Pt(IV) conjugated nano-graphene oxide with synergistic effect to enhance the therapeutic efficacy of Pt drug

Biomaterials

Volumn 51, Issue , 2015, Pages 12-21

  Li, Jingwen ^a   Lyv, Zhonglin ^a   Li, Yanli ^b   Liu, Huan ^a   Wang, Jinkui ^a   Zhan, Wenjun ^a   Chen, Hong ^a   Chen, Huabing ^b   Li, Xinming ^a  

^a SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Graphene oxide; Photothermal; Pt(IV); Synergistic; Theranostic

Indexed keywords

AMMONIA; CELL DEATH; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; GRAPHENE; GRAPHENE OXIDE; INFRARED DEVICES; INFRARED LASERS; LIGHT ABSORPTION; NANOCOMPOSITES; NANOSENSORS; TARGETED DRUG DELIVERY; THERANOSTICS; TUMORS;

HIGH SPECIFIC SURFACE AREA; MULTIFUNCTIONAL NANOCOMPOSITES; NEAR-INFRARED LASER IRRADIATION; NON-INVASIVE IMAGING; PHOTO-THERMAL; PHOTOTHERMAL THERAPY; SYNERGISTIC; THERANOSTIC;

PLATINUM COMPOUNDS;

CISPLATIN; GRAPHENE OXIDE; NANO GRAPHENE OXIDE; NANOCOMPOSITE; PLATINUM COMPLEX; PRODRUG; UNCLASSIFIED DRUG; GRAPHITE; MACROGOL DERIVATIVE; OXIDE; PLATINUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL DEATH; CHEMOTHERAPY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; IRRADIATION; LASER; MOUSE; NEAR INFRARED LASER IRRADIATION; NONHUMAN; PRIORITY JOURNAL; SENSOR; TEMPERATURE; THERANOSTIC PRODRUG DELIVERY SYSTEM; TOXICITY; TUMOR RECURRENCE; ANIMAL; ANTIBODY SPECIFICITY; ATOMIC FORCE MICROSCOPY; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; DRUG RELEASE; DRUG SCREENING; PH; PHOTOTHERAPY; SPECTROFLUOROMETRY; SYNTHESIS; THERANOSTIC NANOMEDICINE; TUMOR CELL LINE;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; DRUG SYNERGISM; FEMALE; GRAPHITE; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; MICROSCOPY, ATOMIC FORCE; NANOCOMPOSITES; ORGAN SPECIFICITY; OXIDES; PHOTOTHERAPY; PLATINUM; POLYETHYLENE GLYCOLS; PRODRUGS; SPECTROMETRY, FLUORESCENCE; THERANOSTIC NANOMEDICINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924907864     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.01.074     Document Type: Article

References (47)

1. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999, 99:2467-2498.
2. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584.
3. Langer T., Zehnhoff-Dinnesen A.A., Radtke S., Meitert J., Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci 2013, 34:458-469.
4. Rieter W.J., Pott K.M., Taylor K.M., Lin W. Nanoscale coordination polymers for platinum-based anticancer drug delivery. JAm Chem Soc 2008, 130:11584-11585.
5. Aryal S., Hu C.-M.J., Zhang L. Polymer-cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano 2009, 4:251-258.
6. Bhirde A.A., Patel V., Gavard J., Zhang G., Sousa A.A., Masedunskas A., et al. Targeted killing of cancer cells invivo and invitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 2009, 3:307-316.
7. Chaudhuri P., Paraskar A., Soni S., Mashelkar R.A., Sengupta S. Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano 2009, 3:2505-2514.
8. Tseng C.-L., Su W.-Y., Yen K.-C., Yang K.-C., Lin F.-H. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30:3476-3485.
9. Yang J., Liu W., Sui M., Tang J., Shen Y. Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery. Biomaterials 2011, 32:9136-9143.
10. Xiao H., Qi R., Liu S., Hu X., Duan T., Zheng Y., et al. Biodegradable polymer-cisplatin(IV) conjugate as a pro-drug of cisplatin(II). Biomaterials 2011, 32:7732-7739.
11. Guo S., Wang Y., Miao L., Xu Z., Lin C.M., Zhang Y., et al. Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano 2013, 7:9896-9904.
12. Oberoi H.S., Nukolova N.V., Kabanov A.V., Bronich T.K. Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev 2013, 65:1667-1685.
13. Xue X., Hall M.D., Zhang Q., Wang P.C., Gottesman M.M., Liang X.-J. Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano 2013, 7:10452-10464.
14. Cheng Z., Dai Y., Kang X., Li C., Huang S., Lian H., et al. Gelatin-encapsulated iron oxide nanoparticles for platinum (IV) prodrug delivery, enzyme-stimulated release and MRI. Biomaterials 2014, 35:6359-6368.
15. Min Y., Li J., Liu F., Yeow E.K., Xing B. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles. Angew Chem Int Ed 2014, 126:1030-1034.
16. Xiao H.H., Noble G.T., Stefanick J.F., Qi R.G., Kiziltepe T., Jing X.B., et al. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy invivo. JControl Release 2014, 173:11-17.
17. Knox R.J., Friedlos F., Lydall D.A., Roberts J.J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986, 46:1972-1979.
18. Go R.S., Adjei A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. JClin Oncol 1999, 17:409-422.
19. Yang H.W., Lu Y.J., Lin K.J., Hsu S.C., Huang C.Y., She S.H., et al. EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy. Biomaterials 2013, 34:7204-7214.
20. Zhang Z., Wang J., Chen C. Near-infrared light-mediated nanoplatforms for cancer thermo-chemotherapy and optical imaging. Adv Mater 2013, 25:3869-3880.
21. Liu T., Wang C., Gu X., Gong H., Cheng L., Shi X., et al. Drug delivery with PEGylated MoS2 nano-sheets for combined photothermal and chemotherapy of cancer. Adv Mater 2014, 26:3433-3440.
22. Tao Y., Ju E.G., Liu Z., Dong K., Ren J.S., Qu X.G. Engineered, self-assembled near-infrared photothermal agents for combined tumor immunotherapy and chemo-photothermal therapy. Biomaterials 2014, 35:6646-6656.
23. Sun X., Liu Z., Welsher K., Robinson J.T., Goodwin A., Zaric S., et al. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res 2008, 1:203-212.
24. Zhang W., Guo Z., Huang D., Liu Z., Guo X., Zhong H. Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide. Biomaterials 2011, 32:8555-8561.
25. Li J.L., Tang B., Yuan B., Sun L., Wang X.G. Areview of optical imaging and therapy using nanosized graphene and graphene oxide. Biomaterials 2013, 34:9519-9534.
26. Sahu A., Choi W.I., Lee J.H., Tae G. Graphene oxide mediated delivery of methylene blue for combined photodynamic and photothermal therapy. Biomaterials 2013, 34:6239-6248.
27. Bai J., Liu Y.W., Jiang X.E. Multifunctional PEG-GO/CuS nanocomposites for near-infrared chemo-photothermal therapy. Biomaterials 2014, 35:5805-5813.
28. Miao W., Shim G., Lee S., Oh Y.K. Structure-dependent photothermal anticancer effects of carbon-based photoresponsive nanomaterials. Biomaterials 2014, 35:4058-4065.
29. Yuan Y., Kwok R.T.K., Tang B.Z., Liu B. Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ. JAm Chem Soc 2014, 136:2546-2554.
30. Giandomenico C.M., Abrams M.J., Murrer B.A., Vollano J.F., Rheinheimer M.I., Wyer S.B., et al. Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entree into orally active platinum(IV) antitumor agents. Inorg Chem 1995, 34:1015-1021.
31. Xiao H., Song H., Yang Q., Cai H., Qi R., Yan L., et al. Aprodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance. Biomaterials 2012, 33:6507-6519.
32. Xiao H., Song H., Zhang Y., Qi R., Wang R., Xie Z., et al. The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy. Biomaterials 2012, 33:8657-8669.
33. Wang H., Zhang Q., Chu X., Chen T., Ge J., Yu R. Graphene oxide-peptide conjugate as an intracellular protease sensor for caspase-3 activation imaging in live cells. Angew Chem Int Ed 2011, 50:7065-7069.
34. Liu Z., Robinson J.T., Sun X., Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. JAm Chem Soc 2008, 130:10876-10877.
35. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J 1997, 326:1-16.
36. Meister A. Glutathione-ascorbic acid antioxidant system in animals. JBiol Chem 1994, 269:9397-9400.
37. Song Y., Suntharalingam K., Yeung J.S., Royzen M., Lippard S.J. Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations. Bioconjug Chem 2013, 24:1733-1740.
38. Kerr J.F., Winterford C.M., Harmon B.V. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994, 73:2013-2026.
39. Green D.R. Apoptotic pathways: the roads to ruin. Cell 1998, 94:695-698.
40. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science 1998, 281:1312-1316.
41. Huff T.B., Tong L., Zhao Y., Hansen M.N., Cheng J.-X., Wei A. Hyperthermic effects of gold nanorods on tumor cells. Nanomedicine 2007, 2:125-132.
42. Hauck T.S., Jennings T.L., Yatsenko T., Kumaradas J.C., Chan W.C.W. Enhancing the toxicity of cancer chemotherapeutics with gold nanorod hyperthermia. Adv Mater 2008, 20:3832-3838.
43. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. JControl Release 2000, 65:271-284.
44. Zhang Z., Wang J., Nie X., Wen T., Ji Y., Wu X., et al. Near infrared laser induced targeted cancer therapy using thermo-responsive polymer encapsulated gold nanorods. JAm Chem Soc 2014, 136:7317-7326.
45. Thompson S.W., Davis L.E., Kornfeld M., Hilgers R.D., Standefer J.C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984, 54:1269-1275.
46. Laurell G., Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 1990, 100:724-734.
47. Hartmann J.T., Kollmannsberger C., Kanz L., Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999, 83:866-869.